<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="362">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156437</url>
  </required_header>
  <id_info>
    <org_study_id>2109416021</org_study_id>
    <nct_id>NCT05156437</nct_id>
  </id_info>
  <brief_title>Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinay Badhwar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and compliance of initial intravenous&#xD;
      (IV) antibiotics followed by oral antibiotic therapy following uncomplicated IVDA&#xD;
      endocarditis. Endocarditis has a high rate of sickness and death, involves a long&#xD;
      hospitalization and a long-term use of IV antibiotics necessitating six (6) weeks of&#xD;
      in-patient hospital stay, and comes with a high cost.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Postoperative patients who have undergone valvar repair or replacement for IVDA endocarditis will be randomized into two arms: Experimental: 2 weeks of postoperative inpatient IV antibiotic therapy followed by 4 weeks of oral therapy with outpatient follow-up; Control: conventional 2 weeks of postoperative inpatient IV antibiotic therapy followed by 4 weeks of IV antibiotic therapy (inpatient or facility supervised if indwelling catheter utilized).&#xD;
Both groups will receive aggressive drug rehabilitation with mandatory participation in a formal psychiatric rehabilitation program for a minimum of 6 weeks (combined inpatient and outpatient), will be followed by Infectious Disease, will undergo monitoring of treatment efficacy with serum antibiotic levels, will undergo surveillance monitoring of treatment efficacy with blood cultures, will participate in a compliance tracking tool for medication administration (e.g. a centrally managed core site mobile Medisafe compliance program.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess all-cause mortality at six (6) months post-surgery.</measure>
    <time_frame>Six months</time_frame>
    <description>To assess all-cause mortality at six (6) months post-surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess all-cause mortality at (12) months post-surgery.</measure>
    <time_frame>One year</time_frame>
    <description>To assess all-cause mortality at (12) months post-surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess recurrent blood culture positive infection.</measure>
    <time_frame>Six months</time_frame>
    <description>To assess recurrent blood culture positive infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess recurrent blood culture positive infection.</measure>
    <time_frame>One year</time_frame>
    <description>To assess recurrent blood culture positive infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess cardiac re-operation.</measure>
    <time_frame>Six months</time_frame>
    <description>To assess cardiac re-operation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess cardiac re-operation.</measure>
    <time_frame>One year</time_frame>
    <description>To assess cardiac re-operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Readmission for recurrent infection or cardiac re-operation</measure>
    <time_frame>Six months</time_frame>
    <description>Readmission for recurrent infection or cardiac re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission for recurrent infection or cardiac re-operation</measure>
    <time_frame>One year</time_frame>
    <description>Readmission for recurrent infection or cardiac re-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of care</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>Cost of care</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Group I (Experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of oral therapy with outpatient follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (Control Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of IV antibiotic therapy (inpatient or facility supervised if indwelling catheter utilized).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin</intervention_name>
    <description>Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin</description>
    <arm_group_label>Group I (Experimental)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline</intervention_name>
    <description>Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline</description>
    <arm_group_label>Group I (Experimental)</arm_group_label>
    <arm_group_label>Group II (Control Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The age of the patient is â‰¥ 18.&#xD;
&#xD;
          -  The patient has undergone an urgent or emergent primary cardiac valvar operation as&#xD;
             treatment for IVDA endocarditis, with blood cultures positive for Streptococcus,&#xD;
             Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative Staphylococci&#xD;
&#xD;
          -  The patient has received 2 weeks of postoperative inpatient IV antibiotic therapy with&#xD;
             negative blood cultures and no residual active infection by imaging (i.e. computerized&#xD;
             axial tomography, echocardiography)&#xD;
&#xD;
          -  The patient has the capacity to participate in a compliance tracking tool for&#xD;
             medication administration (e.g. a centrally managed core site mobile Medisafe&#xD;
             compliance https://www.medisafe.com/) as confirmed by both a physician and a care&#xD;
             management team member&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Residual infection requiring IV antibiotic therapy&#xD;
&#xD;
          -  Any persistent secondary noncardiac infection (e.g. infections of solid organs or&#xD;
             joints)&#xD;
&#xD;
          -  Known poor compliance or deemed incapable to comply with the compliance tracking tool&#xD;
&#xD;
          -  Reduced absorption or inability to receive oral treatment due to a gastrointestinal&#xD;
             disorder&#xD;
&#xD;
          -  Any infection involving a more virulent organisms, such as fungal infections or&#xD;
             infections with Serratia or HACEK infections (Haemophilus, Aggregatibacter,&#xD;
             Cardiobacterium, Eikenella, Kingella).&#xD;
&#xD;
          -  Cancer not otherwise in remission or in need of current or future oncologic therapy&#xD;
&#xD;
          -  Medically immunocompromised state&#xD;
&#xD;
          -  Reoperative valvar operation for IVDA endocarditis&#xD;
&#xD;
          -  History of habitual noncompliance&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Mental incapacity&#xD;
&#xD;
          -  Unable to perform local or institutional medical and psychiatric follow up&#xD;
&#xD;
          -  Unstable home environment&#xD;
&#xD;
          -  Inadequate access to mobile cell service (geographic/rurality)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Fornaresio, PhD</last_name>
    <phone>304.285.1980</phone>
    <email>lisa.fornaresio@wvumedicine.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chad Glaze</last_name>
    <phone>304.598.6092</phone>
    <email>cglaze@wvumedicine.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Virginia University Medicine</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Fornaresio, PhD</last_name>
      <phone>304-285-1980</phone>
      <email>lisa.fornaresio@wvumedicine.org</email>
    </contact>
    <contact_backup>
      <last_name>Chad Glaze</last_name>
      <phone>304.598.6092</phone>
      <email>cglaze@wvumedicine.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vinay Badhwar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Cook, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremiah Hayanga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arif Sarwari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence Wei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joy Juskowich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Fornaresio, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/drugoverdose/data/statedeaths.html</url>
    <description>Centers for Disease Control and Prevention. Drug overdose Deaths</description>
  </link>
  <link>
    <url>http://wonder.cdc.gov</url>
    <description>Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER): Multiple cause of death 1999-2017</description>
  </link>
  <reference>
    <citation>Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, Bruun NE, HÃ¸fsten DE, Fursted K, Christensen JJ, Schultz M, Klein CF, FosbÃ¸ll EL, Rosenvinge F, SchÃ¸nheyder HC, KÃ¸ber L, Torp-Pedersen C, Helweg-Larsen J, TÃ¸nder N, Moser C, Bundgaard H. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019 Jan 31;380(5):415-424. doi: 10.1056/NEJMoa1808312. Epub 2018 Aug 28.</citation>
    <PMID>30152252</PMID>
  </reference>
  <reference>
    <citation>Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review. JAMA Intern Med. 2020 May 1;180(5):769-777. doi: 10.1001/jamainternmed.2020.0555. Review.</citation>
    <PMID>32227127</PMID>
  </reference>
  <reference>
    <citation>Lemaignen A, Bernard L, Tattevin P, Bru JP, Duval X, Hoen B, Brunet-Houdard S, Mainardi JL, Caille A; RODEO (Relais Oral Dans le traitement des Endocardites Ã  staphylocoques ou streptOcoques) and AEPEI (Association pour l'Etude et la PrÃ©vention de l'Endocardite Infectieuse) study groups. Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials. BMJ Open. 2020 Jul 14;10(7):e033540. doi: 10.1136/bmjopen-2019-033540.</citation>
    <PMID>32665381</PMID>
  </reference>
  <reference>
    <citation>Brown E, Gould FK. Oral antibiotics for infective endocarditis: a clinical review. J Antimicrob Chemother. 2020 Aug 1;75(8):2021-2027. doi: 10.1093/jac/dkaa106. Review.</citation>
    <PMID>32240296</PMID>
  </reference>
  <reference>
    <citation>Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018 Jan 4;67(5152):1419-1427. doi: 10.15585/mmwr.mm675152e1.</citation>
    <PMID>30605448</PMID>
  </reference>
  <reference>
    <citation>Wurcel AG, Anderson JE, Chui KK, Skinner S, Knox TA, Snydman DR, Stopka TJ. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infect Dis. 2016 Jul 26;3(3):ofw157. eCollection 2016 Sep.</citation>
    <PMID>27800528</PMID>
  </reference>
  <reference>
    <citation>Kornbau C, Lee KC, Hughes GD, Firstenberg MS. Central line complications. Int J Crit Illn Inj Sci. 2015 Jul-Sep;5(3):170-8. doi: 10.4103/2229-5151.164940.</citation>
    <PMID>26557487</PMID>
  </reference>
  <reference>
    <citation>Badhwar V, Wei LM, Rankin JS. Seeing the entire forest in endocarditis. J Thorac Cardiovasc Surg. 2016 Sep;152(3):681-2. doi: 10.1016/j.jtcvs.2016.05.050. Epub 2016 Jun 4.</citation>
    <PMID>27325495</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Vinay Badhwar</investigator_full_name>
    <investigator_title>Executive Chair, Heart &amp; Vascular Institute</investigator_title>
  </responsible_party>
  <keyword>Intravenous Drug Abuse Endocarditis</keyword>
  <keyword>Oral Antibiotics</keyword>
  <keyword>IV Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Substance Abuse, Intravenous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Ceftaroline fosamil</mesh_term>
    <mesh_term>Oxacillin</mesh_term>
    <mesh_term>Dicloxacillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

